NeuroSense Therapeutics (NRSN) Competitors

$0.84 +0.01 (+1.20%)

As of 02:15 PM Eastern

NRSN vs. CRDF, CYPH, ALDX, ONCY, and CGTX

Should you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include Cardiff Oncology (CRDF), Cypherpunk Technologies (CYPH), Aldeyra Therapeutics (ALDX), Oncolytics Biotech (ONCY), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry.

How does NeuroSense Therapeutics compare to Cardiff Oncology?

NeuroSense Therapeutics (NASDAQ:NRSN) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 7.7% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

NeuroSense Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 905.92%. Cardiff Oncology has a consensus target price of $10.10, indicating a potential upside of 510.27%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe NeuroSense Therapeutics is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cardiff Oncology	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

NeuroSense Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,733.22%. NeuroSense Therapeutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Cardiff Oncology	-7,733.22%	-82.01%	-64.09%

NeuroSense Therapeutics has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Cardiff Oncology	$590K	191.78	-$45.85M	-$0.69	N/A

NeuroSense Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

In the previous week, Cardiff Oncology had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for Cardiff Oncology and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.87 beat Cardiff Oncology's score of 0.94 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroSense Therapeutics	Very Positive
Cardiff Oncology	Positive

Summary

NeuroSense Therapeutics beats Cardiff Oncology on 12 of the 16 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.07	14.93
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 905.92%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

NeuroSense Therapeutics' return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-99.76%	-79.44%
NeuroSense Therapeutics	N/A	N/A	N/A

Cypherpunk Technologies has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Cypherpunk Technologies had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for Cypherpunk Technologies and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.87 beat Cypherpunk Technologies' score of 0.93 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cypherpunk Technologies	Positive
NeuroSense Therapeutics	Very Positive

Summary

NeuroSense Therapeutics beats Cypherpunk Technologies on 9 of the 14 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 8.5% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.57	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

Aldeyra Therapeutics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

NeuroSense Therapeutics' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
NeuroSense Therapeutics	N/A	N/A	N/A

Aldeyra Therapeutics presently has a consensus target price of $5.50, suggesting a potential upside of 215.19%. NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 905.92%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Aldeyra Therapeutics had 22 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 23 mentions for Aldeyra Therapeutics and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.87 beat Aldeyra Therapeutics' score of 0.16 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Neutral
NeuroSense Therapeutics	Very Positive

Summary

NeuroSense Therapeutics beats Aldeyra Therapeutics on 12 of the 14 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

NeuroSense Therapeutics' return on equity of 0.00% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-243.94%
NeuroSense Therapeutics	N/A	N/A	N/A

Oncolytics Biotech presently has a consensus target price of $8.50, suggesting a potential upside of 836.12%. NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 905.92%. Given NeuroSense Therapeutics' higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Oncolytics Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Oncolytics Biotech had 2 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 3 mentions for Oncolytics Biotech and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.87 beat Oncolytics Biotech's score of 0.63 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncolytics Biotech	Positive
NeuroSense Therapeutics	Very Positive

Oncolytics Biotech has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Oncolytics Biotech is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.29	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

Summary

NeuroSense Therapeutics beats Oncolytics Biotech on 8 of the 11 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Cognition Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Cognition Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

NeuroSense Therapeutics' return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Cognition Therapeutics	N/A	-75.46%	-52.72%

NeuroSense Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 14.4% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Cognition Therapeutics had 6 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 7 mentions for Cognition Therapeutics and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.87 beat Cognition Therapeutics' score of 0.84 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroSense Therapeutics	Very Positive
Cognition Therapeutics	Positive

NeuroSense Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 905.92%. Cognition Therapeutics has a consensus target price of $3.33, suggesting a potential upside of 186.12%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe NeuroSense Therapeutics is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

NeuroSense Therapeutics beats Cognition Therapeutics on 9 of the 14 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRSN vs. The Competition

Export

Metric	NeuroSense Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.68M	$3.41B	$6.28B	$12.10B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-1.57	15.30	20.55	25.41
Price / Sales	N/A	303.37	545.88	75.53
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	-16.90	6.85	9.62	6.65
Net Income	-$11.12M	$24.11M	$3.55B	$333.40M
7 Day Performance	-11.03%	-1.57%	-0.36%	-0.58%
1 Month Performance	20.71%	3.83%	5.99%	7.66%
1 Year Performance	-23.18%	71.34%	38.59%	35.36%

NeuroSense Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRSN NeuroSense Therapeutics	3.6417 of 5 stars	$0.85 +1.2%	$8.50 +905.9%	-20.0%	$27.68M	N/A	N/A	10	Positive News
CRDF Cardiff Oncology	1.7319 of 5 stars	$1.62 -0.8%	$10.10 +524.6%	-38.7%	$110.42M	$590K	N/A	20	Upcoming Earnings
CYPH Cypherpunk Technologies	1.3329 of 5 stars	$1.10 flat	N/A	+228.4%	$107.45M	N/A	15.71	40	News Coverage Upcoming Earnings
ALDX Aldeyra Therapeutics	3.0799 of 5 stars	$1.77 +0.3%	$5.50 +211.6%	-19.3%	$105.86M	N/A	N/A	10	Earnings Report Upcoming Earnings Analyst Downgrade Analyst Revision
ONCY Oncolytics Biotech	2.9637 of 5 stars	$0.89 -1.3%	$8.50 +852.9%	+74.0%	$103.70M	N/A	N/A	30	Upcoming Earnings Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRSN) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. CRDF, CYPH, ALDX, ONCY, and CGTX

How does NeuroSense Therapeutics compare to Cardiff Oncology?

Summary

How does NeuroSense Therapeutics compare to Cypherpunk Technologies?

Summary

How does NeuroSense Therapeutics compare to Aldeyra Therapeutics?

Summary

How does NeuroSense Therapeutics compare to Oncolytics Biotech?

Summary

How does NeuroSense Therapeutics compare to Cognition Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. CRDF, CYPH, ALDX, ONCY, and CGTX

How does NeuroSense Therapeutics compare to Cardiff Oncology?

Do insiders & institutionals have more ownership in NRSN or CRDF?

Do analysts rate NRSN or CRDF?

Is NRSN or CRDF more profitable?

Which has preferable valuation and earnings, NRSN or CRDF?

Which has more volatility and risk, NRSN or CRDF?

Does the media refer more to NRSN or CRDF?

Summary

How does NeuroSense Therapeutics compare to Cypherpunk Technologies?

Which has higher earnings & valuation, CYPH or NRSN?

Do analysts prefer CYPH or NRSN?

Is CYPH or NRSN more profitable?

Which has more volatility and risk, CYPH or NRSN?

Do institutionals & insiders hold more shares of CYPH or NRSN?

Does the media favor CYPH or NRSN?

Summary

How does NeuroSense Therapeutics compare to Aldeyra Therapeutics?

Do insiders and institutionals hold more shares of ALDX or NRSN?

Which has stronger earnings and valuation, ALDX or NRSN?

Which has more risk and volatility, ALDX or NRSN?

Is ALDX or NRSN more profitable?

Do analysts prefer ALDX or NRSN?

Does the media favor ALDX or NRSN?

Summary

How does NeuroSense Therapeutics compare to Oncolytics Biotech?

Do insiders and institutionals hold more shares of ONCY or NRSN?

Is ONCY or NRSN more profitable?

Do analysts rate ONCY or NRSN?

Does the media favor ONCY or NRSN?

Which has more volatility & risk, ONCY or NRSN?

Which has higher earnings & valuation, ONCY or NRSN?

Summary

How does NeuroSense Therapeutics compare to Cognition Therapeutics?

Which has better valuation & earnings, NRSN or CGTX?

Is NRSN or CGTX more profitable?

Which has more volatility & risk, NRSN or CGTX?

Do insiders & institutionals hold more shares of NRSN or CGTX?

Does the media prefer NRSN or CGTX?

Do analysts recommend NRSN or CGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools